Top Page
Botanix Pharmaceuticals Limited
(Sydney:BOT)
Botanix Pharmaceuticals Limited (BOT) vs. iShares MSCI Australia ETF (EWA)
Botanix Pharmaceuticals Limited Business Overview & Revenue Model
Botanix Pharmaceuticals Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.79M | 5.79M | 601.82K | 914.97K | 2.75M | 6.89M |
| Gross Profit | 2.02M | 2.02M | -6.12M | -3.05M | -7.54M | 315.80K |
| EBITDA | -80.65M | -80.65M | -15.25M | -12.63M | -15.74M | -10.06M |
| Net Income | -86.40M | -86.40M | -13.87M | -9.15M | -13.17M | -3.33M |
Balance Sheet | ||||||
| Total Assets | 129.10M | 129.10M | 112.46M | 24.84M | 14.04M | 21.95M |
| Cash, Cash Equivalents and Short-Term Investments | 64.97M | 64.97M | 79.31M | 10.25M | 7.29M | 21.55M |
| Total Debt | 32.51M | 32.51M | 0.00 | 0.00 | 122.41K | 259.32K |
| Total Liabilities | 47.80M | 47.80M | 3.73M | 1.88M | 5.89M | 1.15M |
| Stockholders Equity | 81.30M | 81.30M | 108.73M | 22.95M | 8.15M | 20.80M |
Cash Flow | ||||||
| Free Cash Flow | -78.87M | -78.87M | -26.13M | -19.13M | -14.11M | -2.98M |
| Operating Cash Flow | -78.58M | -78.58M | -8.13M | -12.07M | -11.18M | -2.97M |
| Investing Cash Flow | -1.05M | -1.05M | -18.00M | -7.05M | -2.92M | -8.28K |
| Financing Cash Flow | 65.36M | 65.36M | 95.10M | 22.03M | -152.41K | -125.50K |
Botanix Pharmaceuticals Limited Technical Analysis
Botanix Pharmaceuticals Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | AU$613.95M | 16.93 | 15.90% | 0.38% | 7.76% | 1.55% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$677.91M | -10.90 | -35.86% | ― | ― | -19.21% | |
48 Neutral | AU$333.22M | -23.32 | -83.97% | ― | 1271.12% | 36.87% | |
47 Neutral | AU$265.72M | -2.88 | -90.93% | ― | 456.50% | -457.14% | |
42 Neutral | AU$738.77M | -2.95 | ― | ― | -80.08% | 59.91% | |
41 Neutral | AU$276.73M | -28.41 | -89.70% | ― | 42.05% | -0.84% |
Botanix Pharmaceuticals Limited Corporate Events
Botanix Pharmaceuticals has cancelled 6,928,586 fully paid ordinary shares following an employee share scheme buy-back, effective 29 December 2025. The reduction in issued capital marginally tightens the company’s share base and may have implications for existing shareholders by modestly improving per-share metrics and signalling active management of its employee equity programs.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals has completed an employee share scheme buy-back of 6,928,586 ordinary fully paid shares, as disclosed in its final buy-back notification to the ASX dated 30 December 2025. The transaction, recorded with zero consideration payable, appears to be a technical or administrative cancellation of securities under an employee scheme, modestly tightening the company’s share base and potentially affecting equity allocation among existing shareholders without implying a cash outlay by the company.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals has updated the market on its ongoing employee share scheme buy-back, confirming that 6,928,586 ordinary fully paid shares were repurchased on the previous trading day, with no shares bought back before that date. The daily notification underscores the company’s active capital management via buy-backs under its employee equity arrangements, which can influence its share structure and may have implications for existing shareholders’ ownership percentages and the liquidity of BOT shares.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals has notified the market of the issue of 8.75 million unquoted options, each exercisable at A$0.125 and expiring on 24 December 2029, under an employee incentive scheme. The award of these unlisted options, which are not intended to be quoted on the ASX, is designed to align staff incentives with shareholder value creation and may modestly increase potential future dilution if exercised.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals has applied for quotation on the ASX of 4.6 million new ordinary fully paid shares, following the issue of these securities on 18 December 2025. The additional quotation expands the company’s listed share capital, potentially enhancing liquidity in its stock and providing greater flexibility for capital management and future corporate activities.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals Limited has announced a buy-back of ordinary fully paid shares under an employee share scheme. This move is part of the company’s strategy to manage its capital structure and incentivize its employees, potentially enhancing shareholder value and aligning employee interests with company goals.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals announced the results of its 2025 Annual General Meeting, where all resolutions were passed except for the approval of the Remuneration Report. The meeting included the re-election of directors and the ratification of placement shares issued to investors, indicating continued support from shareholders and strategic positioning in the market.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals Limited has successfully transitioned into a commercial revenue-generating company following the acquisition and FDA approval of its lead asset, Sofdra. The company reported significant growth in sales and revenue in its second full quarter post-launch, with a 50% increase in total prescriptions and a 65% rise in net revenue. The expansion of its sales force and the development of a differentiated fulfillment platform have been pivotal in driving this success, positioning Botanix strongly within the dermatology market.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals announced that it has received a partial waiver from the ASX Listing Rule 7.5.4, which would have allowed the company to seek shareholder approval for the ratification of a loan facility agreement at its annual general meeting. However, the company has decided not to rely on this waiver, as its current placement capacity is sufficient to meet its obligations. This decision indicates a strong financial position and operational flexibility, potentially reassuring stakeholders about the company’s ability to manage its financial commitments without diluting shareholder value.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals announced that its CEO, Dr. Howie McKibbon, will present at the Canaccord Drug and Device Healthcare Conference in Noosa. The presentation aims to engage institutional investors and is part of a broader investor roadshow hosted by Canaccord Genuity. This event is significant as it provides Botanix an opportunity to showcase its FDA-approved product, Sofdra®, and potentially strengthen its market position and investor relations.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals Limited has released its Q1 FY26 investor update, highlighting the company’s strategic plans and market positioning. The update includes insights into the company’s operations, potential regulatory approvals, and the commercial prospects of its product candidates, such as Sofdra®. This announcement is significant for stakeholders as it outlines Botanix’s future direction and potential market impact, although it is accompanied by the usual risks and uncertainties inherent in the pharmaceutical industry.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals Limited has announced its Annual General Meeting scheduled for November 20, 2025, in Perth, Western Australia. Shareholders are encouraged to lodge their proxy forms online or via other specified methods before the meeting. This meeting is crucial for stakeholders as it provides an opportunity to discuss the company’s strategic direction and operational updates, potentially impacting future business decisions.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals Limited has announced its Annual General Meeting (AGM) scheduled for November 20, 2025, in Perth, Western Australia. The meeting will address key business matters, including the consideration of financial reports and a non-binding resolution on the remuneration report for the year ended June 30, 2025. This AGM is crucial for shareholders to engage with the company’s financial and strategic direction, impacting its governance and stakeholder relations.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals Limited has announced the cessation of several securities due to the lapse of conditional rights, as the conditions for these securities have not been met or have become incapable of being satisfied. This announcement may impact the company’s financial structuring and could influence investor perceptions, potentially affecting its market positioning.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals Limited announced the issuance of 4.5 million performance rights and 13.5 million options exercisable at $0.11 each, expiring in 2030, as part of an employee incentive scheme. This move is expected to enhance employee engagement and align their interests with the company’s long-term growth objectives, potentially strengthening Botanix’s position in the pharmaceutical industry.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.